Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis

Trial Profile

Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Prasugrel (Primary) ; Aspirin
  • Indications Coronary thrombosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Oct 2017 Planned number of patients changed from 120 to 84.
    • 19 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 22 Mar 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top